Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Radiofrequency Ablation Accompanied With Spontaneous Sorafenib Administration in the Treatment of Early to Intermediate Stage Hepatocellular Carcinoma: a Prospective Multicenter Cohort Study.(REASSESS)

NCT02187081 is registered in ClinicalTrials.gov with Southwest Hospital, China as lead sponsor.

NCT NCT02187081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02187081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Radiofrequency Ablation Accompanied With Spontaneous Sorafenib Administration in the Treatment of Early to Intermediate Stage Hepatocellular Carcinoma: a Prospective Multicenter Cohort Study.(REASSESS)
Lead sponsor
Southwest Hospital, China
Phase
Not applicable
Overall status
Unknown status
Start date
March 15, 2017
Completion date
December 31, 2018
Enrollment
380 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hcc